Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 1380

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1A
Chunk 1380
---
 and diversion of our management’s time and attention in order to develop acquired products, product candidates
    or technologies;

    ●
    incurrence
    of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;

    ●
    higher-than-expected
    transaction and integration costs;

    ●
    write-downs
    of assets or goodwill or impairment charges;

    ●
    increased
    amortization expenses;

    ●
    difficulty
    and cost in combining the operations and personnel of any acquired businesses or product lines with our operations and personnel;

    ●
    impairment
    of relationships with key suppliers or customers of any acquired businesses or product lines due to changes in management and ownership;
    and

    ●
    inability
    to retain key employees of any acquired businesses.

Accordingly,
although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any
transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business,
financial condition and results of operations.

56

Risks
Related to Our Common Stock

If
we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price
of our common stock and our ability to access the capital markets could be negatively impacted.

Nasdaq
has established certain standards for the continued listing of a security on the Nasdaq Capital Market. The standards for continued listing
include, among other things, that the minimum bid price for the listed securities not fall below $1.00 per share for a period of 30 consecutive
trading days and that we maintain a minimum of $2,500,000 in stockholders’ equity.

On
January 31, 2025, we were notified, or the Notification Letter, by the Nasdaq Listing Qualifications that we are not in compliance with
the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2), or the Rule, for continued listing on The Nasdaq Capital
Market. The Notification Letter provides that the Company has 180 calendar days, or until July 30, 2025, to regain compliance with the
Rule. To regain compliance, the bid price of our common stock must have a closing bid price of at least $1.00 per share for a minimum
of 10 consecutive business days. In the event we do not regain compliance by July